Drug Details
General Information of the Drug (ID: DR7371) | ||||
---|---|---|---|---|
Name |
Diethylpropion
|
|||
Synonyms |
Amfepramone; DIETHYLPROPION; Diethylpropione; Anorex; Tepanil; 90-84-6; Frekentine; Danylen; Dobesin; Magrene; Tylinal; alpha-Benzoyltriethylamine; Amfepramonum; Prefamone; Regenon; alpha-Diethylaminopropiophenone; Anfepramona; 1-Propanone, 2-(diethylamino)-1-phenyl-; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; 2-(Diethylamino)propiophenone; Amfepramone [INN]; 1-Phenyl-2-diethylamino-1-propanone; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Moderatan; Tenuate; Amfepramon; Amfepramone hydrochloride; DEA No. 1610; Propiophenone, 2-(diethylamino)-; Amfepramone (INN); Amphepramon; Amphepramone; Nopropiophenone; Adiposon; Neobes; Tenuate Dospan; Amphepramonum hydrochloride; Diethylpropione hydrochloride; Cegramine; Obesitex; Silutin; Derfon; Regenon hydrochloride; CHEBI:4530; Anfamon; Keramik; Keramin; Modulor; Parabolin; UNII-I535TOV6LY; UNII-P1A5AE6Q2R; C06954; D07444; Tenuate hydrochloride; (+)-Amfepramone; (-)-Amfepramone; UR 1423; (+-)-diethylpropion; Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone, (+)-; Amfepramone, (-)-; Fenyl-(1-diethylaminoethyl)keton; HSDB 3059; I535TOV6LY; P1A5AE6Q2R; Diethylpropion, (+}-; Diethylpropion, (-)-; NCGC00167475-01; EINECS 202-019-1; BRN 2804400; 1-Phenyl-2-diethylaminopropanone-1 hydrochloride; Propiophenone, 2-(diethylamino)-, hydrochloride; Propiophenone, 2-diethylamino-; (+)-2-Diethylaminopropiophenone; (-)-2-Diethylaminopropiophenone; (+/-)-diethylpropion; SCHEMBL27330; 1-Propanone, 2-(diethylamino)-1-phenyl-, (+)-; 1-Propanone, 2-(diethylamino)-1-phenyl-, (-)-; 4-14-00-00144 (Beilstein Handbook Reference); GTPL7161; CHEMBL1194666; DTXSID6022929; MFCD00056154; AKOS025401369; DIETHYLPROPION, DONYLEN,DOBESIN; DB00937; J4.327C; MCULE-3905795013; 2-Diethylaminopropiophenone hydrochloride; 39648-49-2; 39648-50-5; AC-13099; 2-(Diethylamino)-1-phenyl-1-propanone #; 1-Phenyl-2-diethylamino-1-propanone hydrochloride; Q2356505; BRD-A37288617-003-01-4
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Obesity [ICD-11: 5B81] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C13H19NO
|
|||
PubChem CID | ||||
Canonical SMILES |
CCN(CC)C(C)C(=O)C1=CC=CC=C1
|
|||
InChI |
1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
|
|||
InChIKey |
XXEPPPIWZFICOJ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 90-84-6
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Topiramate | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
Low doses of the diethylpropion + topiramate combination can potentiate the anorectic effect of individual drugs with a better safety profile. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Norepinephrine transporter (NET) | Molecule Info | [1] | |
Serotonin transporter (SERT) | Molecule Info | [1] | ||
KEGG Pathway | Serotonergic synapse | Click to Show/Hide | ||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | 5HT1 type receptor mediated signaling pathway | Click to Show/Hide | ||
2 | 5HT2 type receptor mediated signaling pathway | |||
3 | 5HT3 type receptor mediated signaling pathway | |||
4 | 5HT4 type receptor mediated signaling pathway | |||
5 | Adrenaline and noradrenaline biosynthesis | |||
Reactome | Na+/Cl- dependent neurotransmitter transporters | Click to Show/Hide | ||
WikiPathways | Monoamine Transport | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | NRF2 pathway | |||
4 | Synaptic Vesicle Pathway | |||
5 | Serotonin Transporter Activity | |||
6 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
